Rilonacept, known in scientific literature as IL-1 Trap, is an Interleukin-1 (IL-1) blocker that is being clinically evaluated for the prevention of gout flares in patients who are initiating uric acid-lowering therapy.
Rilonacept is a fusion protein that incorporates parts of the IL-1 receptor. It was designed by Regeneron scientists to attach to the pro-inflammatory protein interleukin-1 (IL-1) before IL-1 can bind to cell-surface receptors and generate signals that trigger inflammation.
Development Phase: Phase 3 UP SURGE study, a one-year safety evaluation of rilonacept for the prevention of gout flares in patients who are initiating uric acid-lowering therapy.
This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.